CAMBRIDGE - Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease, today announced that it has raised
The financing round included the company's founder, Flagship Pioneering, and a number of top-tier investors.
'Alltrna's platform optimizes tRNA nucleotide sequence and modifications to turn tRNA's sophisticated biology into programmable medicines with powerful potential therapeutic properties,' said
'This is an important milestone for Alltrna as the company advances the first platform to unlock tRNA biology and systematically design, program, and deliver first-in-class tRNA medicines,' said
tRNAs not only play a central role in the translation of mRNA into proteins but also are programmable molecules with a diverse biology of sequences and modifications. There exist more than 10^34 tRNA sequences with more than 120 natural and synthetic modifications possible for each nucleotide, yielding the potential to generate more engineered, modified tRNA oligonucleotides than atoms in the universe. Alltrna's platform uniquely combines internal expertise and proprietary machine learning tools to harness the combinatorial potential of tRNA sequences and modifications that are key to structure, function, and stability. Alltrna recently presented data validating the potential of its platform to design, modify, produce, and deliver engineered, modified tRNA oligonucleotides with significantly increased potency and activity for the in vivo readthrough of PTC mutations to restore the production of full-length proteins, independent of gene and mutation location.
'Alltrna has made a big leap in tRNA biology to realize the potential of this powerful new class of medicines to truly accelerate drug development for genetically driven diseases. Without the limitation of developing a new genetic medicine for each disease, Alltrna has the opportunity to scale a whole new field of programmable medicines,' said
About Stop Codon Disease
Stop Codon Disease encompasses thousands of rare and common diseases that stem from premature termination codons (PTC) also called nonsense mutations, where the code for an amino acid has been mutated into a premature 'stop' codon. This results in a truncated or shortened protein product with no or altered biological activity that causes disease. Approximately 10% of all people with a genetic disease have Stop Codon Disease, representing approximately 30 million people worldwide. Alltrna is engineering tRNA medicines that can read these PTC mutations and deliver the desired amino acid, thereby restoring the production of the full-length protein.
About Alltrna
Alltrna unlocks tRNA biology to correct disease. The company's platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation. Alltrna was founded in 2018 by Flagship Pioneering.
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its
Contact:
Email: jessica@litldog.com
Tel: +1.858.344.8091
(C) 2023 Electronic News Publishing, source